Join
Live feed
·
PRReleasevia Quantisnow
iBio Inc. logo

iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy

ByQuantisnow·Wall Street's wire, on your screen.
IBIO· iBio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IBIO (iBio Inc.) and more on Quantisnow.